Recent News and Upcoming Events

Recent News

• June 10, 2020

  Vermillion Set to Join Russell 3000 Index

  For a pdf of this press release please click here AUSTIN, Texas — June 9, 2020 — Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it is set to join the broad-market Russell 3000(R) Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after…

• May 15, 2020

  Vermillion Reports First Quarter 2020 Financial Results

  For a link to a pdf of the press release please click here AUSTIN, Texas — May 14, 2020 — Vermillion, Inc. (Nasdaq: VRML), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the first quarter March 31, 2020. “Despite late first quarter challenges from COVID-19, we delivered strong…

• May 1, 2020

  Vermillion to Report First Quarter 2020 Financial Results on May 14

  For a pdf of the press release click here AUSTIN, Texas, April 30, 2020 – Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will report financial results for the first quarter ended March 31, 2020, on Thursday, May 14, 2020, after the market close, followed by…

• April 14, 2020

  Vermillion Inc. Announces ASPiRA LABS Now Credentialed as Florida State Medicaid Provider

  Fourth largest Medicaid population in the U.S. For a pdf of this press release click here AUSTIN, Texas, April 14, 2020 –Vermillion, Inc. (NASDAQ: VRML) today announced its wholly owned subsidiary, ASPiRA LABS, is now credentialed with Florida’s State Medicaid program for an estimated additional 3.6 million credentialed Medicaid lives. Florida has the fourth largest state…

• March 27, 2020

  Vermillion Announces Cigna Preferred Contract Coverage for OVA1, OVERA and Genetics Testing

  For a pdf of this press release click here AUSTIN, Texas, March 27, 2020 – Vermillion, Inc. (NASDAQ: VRML), a bioinformatics-based women’s health company focused on gynecologic disease, announced yesterday that its wholly owned subsidiary, ASPiRA Labs, has signed a national preferred agreement with Cigna. This contract includes OVA1, (Multivariate Index Assay, MIA) our ACOG endorsed…